Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,174.80
(
1.94%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
92.92
(
-2.67%
)
Bitcoin
74,258.59
(
0.09%
)
News Focus
News Focus
Post# of 447325
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

HDGabor

Send PM Follow Ignore
Followers 142
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

HDGabor

Re: smarterer post# 148326

Monday, 10/08/2018 11:08:42 AM

Monday, October 08, 2018 11:08:42 AM

Post# of 447325
s-

They ought to be able to get new use patents on several other diseases by then … volume pipeline built up with Vascepa that allows them to drive pricing to such an extent that it inhibits the ability of others--even generics--to compete

Yes … but they have an agreement in place with TEVA
- they could launch gV by 2029
- they could match / compete with Amarin's price … which will be significantly lower after launch of gV

Best,
G

The eagle does not catch flies …

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News